Documentation
Description:
VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoints are objective response rate (CR+PR), toxicity, progression-free survival, overall survival and treatment compliance. Formalin fixed paraffin embedded (FFPE) tumour blocks are held at the Orchid Tissue Laboratory and Barts and The London School of Medicine and Dentistry.
Coverage
Spatial:
United Kingdom,England
Typical Age Range:
40-150
Provenance
Temporal
Start Date:
01 January 2016
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
The Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress